Compare Brookfield Infrastructure Partners LP (BIP) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brookfield Infrastructure Partners LP vs IDEXX Laboratories, Inc. — how do they compare? Brookfield Infrastructure Partners LP trades at $39.54 (market cap $18.10B), while IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2.6× Brookfield Infrastructure Partners LP's market cap, and Brookfield Infrastructure Partners LP pays a 4.62% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| BIP | IDXX | |
|---|---|---|
Market Cap | $18.10B | $46.22B |
Sector | Industrials | Health |
52-Week High | $42.62 | $766.68 |
52-Week Low | $29.81 | $526.44 |
Enterprise Value | $77.05B | $47.12B |
Dividend Yield | 4.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Brookfield Infrastructure Partners (BIP) trades at $39.55, up 4.13% in the last session, with a bullish technical signal and strong analyst support. Recent earnings misses contrast with positive cash flow trends and a 6.97 EV/EBITDA valuation. News highlights dividend appeal and corporate simplification efforts, while institutional interest remains robust.
Outlook is cautiously optimistic given high analyst buy ratings and a $44.67 price target, but risks include earnings volatility and margin pressure. The stock offers income potential with dividends, though net income declined to $652M in 2026. Investors should weigh solid infrastructure assets against execution challenges.
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Brookfield Infrastructure Partners LP
Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
